Cardiac toxicity of the echinocandins: chance or cause and effect association?

Area of Science:

• Cardiology
• Infectious Diseases
• Pharmacology

Background:

• Fungal infections are a significant threat to critically ill and immunocompromised patients.
• Echinocandin antifungals offer a seemingly safer alternative to older antifungal agents.
• Recent evidence prompts a review of potential cardiac toxicity associated with echinocandins.

Purpose of the Study:

• To critically evaluate the cardiac toxicity of echinocandin antifungals.
• To review recent case reports and laboratory findings concerning echinocandin-induced cardiotoxicity.
• To investigate the potential mechanisms underlying cardiac adverse effects.

Main Methods:

• Review of published case reports detailing cardiac events post-echinocandin initiation.
• Analysis of ex vivo laboratory studies exposing cardiac tissue to echinocandin agents.
• Hypothesizing the mechanism of cardiac toxicity based on experimental and clinical data.

Main Results:

• Three case reports documented cardiac decompensation following administration of anidulafungin and caspofungin.
• Ex vivo studies demonstrated significantly reduced cardiac contractility in rat hearts exposed to anidulafungin and caspofungin.
• Mitochondrial toxicity is proposed as the primary mechanism for observed cardiac dysfunction.

Conclusions:

• Clinical findings strongly corroborate ex vivo laboratory results regarding echinocandin cardiotoxicity.
• The observed cardiac toxicity associated with anidulafungin and caspofungin appears to be a cause-and-effect relationship.
• Healthcare providers should be aware of the potential for cardiac adverse events with certain echinocandin antifungals.